Clearmind Medicine Inc.
CMND · NASDAQ
4/30/2025 | 1/31/2025 | 10/31/2024 | 7/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.95 | -4.05 | 1.04 | -0.25 |
| FCF Yield | -0.54% | -0.51% | -0.46% | -0.48% |
| EV / EBITDA | -153.67 | -239.27 | -195.46 | -157.11 |
| Quality | ||||
| ROIC | -56.56% | -52.85% | -56.37% | -42.08% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.14 | 1.40 | 1.18 | 1.23 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 13.20% | -16.58% | 3.66% | 5.54% |
| Safety | ||||
| Net Debt / EBITDA | 3.43 | 5.67 | 5.53 | 5.23 |
| Interest Coverage | -166.11 | -171.68 | -43.87 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -3,575.11 | -4,890.91 | -4,112.67 | -1,639.59 |